Nature Medicine
10, 145 - 147 (2004)
Published online: 25 January 2004; | doi:10.1038/nm988
There is a Corrigendum (June 2004) associated with this Brief Communication.
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G Willett1, Yves Boucher1, 10, Emmanuelle di Tomaso1, 10, Dan G Duda1, 10, Lance L Munn1, 10, Ricky T Tong1, 10, Daniel C Chung2, Dushyant V Sahani3, Sanjeeva P Kalva3, Sergey V Kozin1, Mari Mino4, Kenneth S Cohen5, David T Scadden5, Alan C Hartford1, Alan J Fischman6, Jeffrey W Clark7, David P Ryan7, Andrew X Zhu7, Lawrence S Blaszkowsky7, Helen X Chen9, Paul C Shellito8, Gregory Y Lauwers4
& Rakesh K Jain11
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. 2
Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. 3
Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. 4
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. 5
AIDS Research Center/Experimental Hematology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. 6
Department of Nuclear Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. 7
Division of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. 8
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. 9
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland 20852, USA. 10
These authors contributed equally to this work.
Correspondence should be addressed to Christopher G Willett cwillett@partners.org or Rakesh K Jain jain@steele.mgh.harvard.eduThe effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|
